Free to follow every thread. No paywall, no dead ends.
Parkinson's disease | HearLore
Parkinson's disease
In 1817, an English physician named James Parkinson published a monograph titled An Essay on the Shaking Palsy, describing six clinical cases he had observed on the streets near Hoxton Square in London. He identified three cardinal symptoms: tremor, postural instability, and what he termed paralysis, which we now understand as rigidity or bradykinesia. Parkinson speculated that the disease was caused by trauma to the spinal cord, a theory that would be disproven over the next century. Little discussion or investigation into this shaking palsy occurred until 1861, when the French neurologist Jean-Martin Charcot began expanding Parkinson's description. Charcot added bradykinesia as a fourth cardinal symptom and, in 1877, renamed the disease after Parkinson, noting that the tremor suggested by the original name was not present in all cases. Before Parkinson's detailed account, incomplete descriptions of similar symptoms had appeared in ancient texts, including a Nineteenth Dynasty Egyptian papyrus, the ayurvedic text Charaka Samhita, and a discussion of tremors by Leonardo da Vinci. A systematic description was even found in the Hungarian medical text Pax corporis written by Ferenc Pápai Páriz in 1690, some 120 years before Parkinson, though it was published only in Hungarian and remained largely unknown to the wider medical community.
The Silent Invasion
The disease begins its work long before the first tremor appears, often starting outside the brain in the enteric nervous system or the olfactory bulb. In 2002, Heiko Braak and colleagues proposed that Parkinson's disease is triggered by a neuroinvasion of some unknown pathogen that enters through the nasal cavity and is swallowed into the digestive tract. This pathogen initiates Lewy pathology in both the gut and the nose, and the alpha-synuclein pathology then travels from the gut to the central nervous system through the vagus nerve. This theory explains the presence of Lewy pathology in both the enteric nervous system and olfactory tract neurons, as well as clinical symptoms such as loss of smell and gastrointestinal problems. Environmental toxicants ingested in a similar manner might also trigger the disease. By the time motor symptoms appear, 50 to 80 percent of all dopaminergic neurons in the substantia nigra have already degenerated. The hallmark of the disease is the formation of protein aggregates, beginning with alpha-synuclein fibrils and followed by Lewy bodies and Lewy neurites. These aggregates are pathogenic and can spread to neighboring healthy neurons, seeding new aggregates in a process that resembles the behavior of prions.
The Dopamine Deficit
The core of Parkinson's disease lies in the gradual decay and loss of dopamine-producing neurons in a brain region called the substantia nigra and other related cell groups in the brainstem. This loss of dopamine leads to movement abnormalities, causing the categorization of Parkinson's as a movement disorder. The death of these neurons reduces available dopamine in the striatum, which in turn affects circuits controlling movement in the basal ganglia. The four cardinal motor symptoms of Parkinson's, slowed movements, postural instability, rigidity, and tremor, are collectively termed parkinsonism. Appearing in 70 to 75 percent of those with PD, tremor is often the predominant motor symptom. A classic parkinsonian tremor is pill-rolling, a resting tremor in which the thumb and index finger make contact in a circular motion at a frequency of 4 to 6 Hz. Bradykinesia describes difficulties in motor planning, beginning, and executing, resulting in overall slowed movement with reduced amplitude that affects sequential and simultaneous tasks. Rigidity refers to a feeling of stiffness and resistance to passive stretching of muscles, while postural instability typically appears in later stages, leading to impaired balance and falls. Beyond these cardinal features, other motor deficits such as gait disturbances, speech problems, and altered handwriting known as micrographia are common.
When did James Parkinson publish his monograph on the shaking palsy?
James Parkinson published his monograph titled An Essay on the Shaking Palsy in 1817. He described six clinical cases he had observed on the streets near Hoxton Square in London.
What are the four cardinal symptoms of Parkinson's disease identified by Jean-Martin Charcot?
Jean-Martin Charcot identified four cardinal symptoms of Parkinson's disease in 1877 when he renamed the condition. These symptoms include tremor, postural instability, rigidity, and bradykinesia.
How does the Braak hypothesis explain the origin of Parkinson's disease symptoms?
The Braak hypothesis proposes that Parkinson's disease begins outside the brain in the enteric nervous system or the olfactory bulb. A pathogen enters through the nasal cavity and travels to the central nervous system via the vagus nerve, initiating Lewy pathology in the gut and nose.
Which genetic variants are responsible for autosomal dominant inheritance of Parkinson's disease?
Notable genetic risk variants for autosomal dominant inheritance of Parkinson's disease include SNCA, LRRK2, and VPS35. LRRK2 is the most common autosomal dominant variant, responsible for 1 to 2 percent of all Parkinson's disease cases.
What is the current status of disease-modifying therapies for Parkinson's disease as of 2025?
As of 2025, no disease-modifying therapies exist that reverse or slow neurodegeneration in Parkinson's disease. Treatment currently focuses on alleviating symptoms using medications like levodopa or invasive procedures such as deep brain stimulation.
Who founded the Michael J. Fox Foundation and when was it established?
Actor Michael J. Fox founded the Michael J. Fox Foundation in 2000 after being diagnosed with Parkinson's disease at 29 years old. The foundation has raised over 2 billion dollars for Parkinson's research.
While motor symptoms dominate the public perception of Parkinson's disease, non-motor symptoms such as autonomic nervous system failures, sleep abnormalities, and behavioral changes may appear at any stage of the disease. Neuropsychiatric symptoms such as anxiety, apathy, depression, hallucination, and impulse control disorders occur in up to 60 percent of those with PD. These symptoms often precede motor symptoms, vary with disease progression, and may appear at any stage including the prodromal phase. Autonomic nervous system failures, known as dysautonomia, can appear at any stage and are among the most debilitating symptoms, greatly reducing quality of life. Chiefly, orthostatic hypotension, a sustained blood pressure drop of at least 20 mmHg systolic or 10 mmHg diastolic after standing, occurs in 30 to 50 percent of cases. Other autonomic failures include gastrointestinal issues such as chronic constipation, impaired stomach emptying, and excessive salivation. Sleep disorders are highly prevalent, affecting up to 98 percent of patients, including insomnia, excessive daytime sleepiness, and REM sleep behavior disorder. Sensory deficits appear in up to 90 percent of people with PD, and an impaired sense of smell is also prevalent. Individuals often struggle with spatial awareness, recognizing faces and emotions, and may experience challenges with reading and double vision.
The Genetic Puzzle
Parkinson's disease has no single cause; rather, genetic and environmental factors interact to affect critical cellular processes. Genetically, about 5 to 10 percent of cases are familial, while others are classed as idiopathic with no clearly identifiable cause. Variations in specific genes have been identified as risk factors and linked to contributing neural mechanisms. Notable genetic risk variants include SNCA, which encodes alpha-synuclein, LRRK2, and VPS35 for autosomal dominant inheritance, and PRKN, PINK1, and DJ1 for autosomal recessive inheritance. LRRK2 is the most common autosomal dominant variant, responsible for 1 to 2 percent of all PD cases and 40 percent of familial cases. Environmentally, exposures to pesticides, metals, solvents, other toxicants, and air pollution are increasingly seen as major risk factors in PD development. The brain is particularly vulnerable to chemicals that are able to cross the blood-brain barrier. Traumatic brain injury and Type 2 diabetes are additional risk factors. The cumulative effects of many different environmental exposures over a lifetime interact with underlying genetic factors to influence PD development and progression. Despite the complexity, exercise, coffee consumption, and diets rich in fruits, vegetables, whole grains, and fish are protective factors associated with lower risk of PD.
The Treatment Paradox
As of 2025, no disease-modifying therapies exist that reverse or slow neurodegeneration, and treatment focuses on alleviating symptoms. Levodopa is the most widely used and most effective therapy, the gold standard for PD treatment. The compound occurs naturally and is the immediate precursor for dopamine synthesis in the dopaminergic neurons of the substantia nigra. Despite its efficacy, levodopa poses several challenges. Its administration has been called the pharmacologist's nightmare. Its metabolism outside the brain can cause nausea and vomiting, and long-term use may induce dyskinesia and motor fluctuations. Dopamine agonists are an alternative or complement to levodopa therapy, activating dopamine receptors in the striatum with reduced risk of motor fluctuations and dyskinesia. However, after five years of use, impulse-control disorders may occur in over 40 percent of those taking dopamine agonists. Invasive procedures such as deep brain stimulation may be used when medications are ineffective. DBS involves the implantation of electrodes called neurostimulators, which send electrical impulses to specific parts of the brain. DBS for the subthalamic nucleus and globus pallus interna has high efficacy for up to 2 years, but long-term efficacy is unclear and likely decreases with time.
The Public Face
In the 21st century, the diagnosis of Parkinson's disease among notable figures has increased the public's understanding of the disorder. Actor Michael J. Fox was diagnosed with PD at 29 years old, and has used his diagnosis to increase awareness of the disease. The Michael J. Fox Foundation, which he founded in 2000, has raised over 2 billion dollars for Parkinson's research. Boxer Muhammad Ali showed signs of PD when he was 38, but was undiagnosed until he was 42, and has been called the world's most famous Parkinson's patient. Cyclist and Olympic medalist Davis Phinney, diagnosed with PD at 40, started the Davis Phinney Foundation in 2004 to support PD research. Musician Ozzy Osbourne was diagnosed with PD and performed a the 5th of July 2025, farewell reunion concert with the band he co-founded, Black Sabbath, weeks before his death. The event raised over 190 million dollars, some of which went to Parkinson's disease research. The birthday of James Parkinson, the 11th of April, has been designated as World Parkinson's Day, and a red tulip was chosen by international organizations as the symbol of the disease in 2005. Advocacy organizations include the National Parkinson Foundation, which has provided more than 180 million dollars in care, research, and support services since 1982, and the Parkinson's Disease Foundation, which has distributed more than 115 million dollars for research and nearly 50 million dollars for education and advocacy programs since its founding in 1957.
The Future Horizon
Active research directions include the search for new animal models of the disease and development and trial of gene therapy, stem cell transplants, and neuroprotective agents. Drugs that prevent alpha-synuclein oligomerization and aggregation or promote their clearance are under active investigation, and potential therapeutic strategies include small molecules and immunotherapies including vaccines and monoclonal antibodies. As the gut microbiome in PD is often disrupted and produces toxic compounds, fecal microbiota transplants might restore a healthy microbiome and alleviate various motor and non-motor symptoms. In contrast to other neurodegenerative disorders, many PD symptoms can be attributed to the loss of a single cell type. Consequently, dopaminergic neuron regeneration is a promising therapeutic approach. Although most initial research sought to generate dopaminergic neuron precursor cells from fetal brain tissue, pluripotent stem cells, particularly induced pluripotent stem cells, have become an increasingly popular tissue source. Both fetal and iPSC-derived DA neurons have been transplanted into patients in clinical trials. Although some individuals have seen improvement, the results are highly variable. Adverse effects, such as dyskinesia arising from excess dopamine release by the transplanted tissues, have also been observed. Gene therapy for PD seeks to restore the healthy function of dopaminergic neurons in the substantia nigra by delivering genetic material, typically through a viral vector, to these diseased cells.